Skip to main content
Shilpa Medicare Ltd. logo

Shilpa Medicare Ltd. — Investor Relations & Filings

Ticker · SHILPAMED ISIN · INE790G01031 LEI · 3358002PKUL8S2RNJO60 BSE.NS Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-07-04 Regulatory Filings
Country IN India
Listing BSE.NS SHILPAMED

About Shilpa Medicare Ltd.

https://vbshilpa.com/

Shilpa Medicare Ltd. is a research-led organization specializing in the development, manufacture, and commercialization of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the oncology segment, producing a wide range of high-potency anti-cancer drugs. Its capabilities extend to diverse therapeutic areas, including ophthalmology, dermatology, and biosimilars. Shilpa Medicare operates manufacturing facilities compliant with international regulatory standards such as the USFDA and EU-GMP. The organization emphasizes complex chemistry and advanced drug delivery systems, offering a portfolio that includes oral solids, injectables, and transdermal patches. Through its R&D infrastructure, the company provides contract research and manufacturing services to global partners, supporting the lifecycle of generic and innovative pharmaceutical products.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing about the completion of a GMP inspection audit by the Brazilian regulatory authority ANVISA for a subsidiary of Shilpa Medicare Limited. It mentions the audit dates, results, and the company's commitment to respond with a CAPA plan. The document is short (1578 characters), does not contain any financial data, financial statements, or detailed report content. It is an announcement of an event related to regulatory compliance and audit results, not a full audit report or annual report. It is also not a certification or officer attestation document but an official regulatory announcement. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-04 English
Credit Rating- Revision
Capital/Financing Update Classification · 95% confidence The document is a detailed communication from Shilpa Medicare Limited to stock exchanges regarding a revision in credit ratings by India Ratings & Research (Fitch Group). It includes detailed rating actions, instrument types, sizes, and outlook revisions for the company and its subsidiary. The document contains no financial statements or comprehensive financial performance data but focuses on credit rating updates and related disclosures. It is not an earnings release, annual report, or management discussion but rather a regulatory announcement about credit rating changes. The document is substantive and not a brief announcement of a report publication. Given the nature of the content—credit rating revision and related disclosures—it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including credit rating revisions.
2025-07-02 English
Amalgamation/Merger
M&A Activity Classification · 95% confidence The document is a formal communication from Shilpa Medicare Limited to stock exchanges regarding the sanction of a Scheme of Amalgamation by the National Company Law Tribunal (NCLT). It includes detailed legal and regulatory information about the merger process, references to the Companies Act, 2013, and compliance with SEBI regulations. The document contains the NCLT order approving the scheme, details about the petition, compliance with procedural requirements, and financial and legal observations related to the merger. This is a regulatory announcement about a corporate restructuring event (amalgamation) and not a financial report, earnings release, or management discussion. It is not a proxy statement, voting result, or remuneration report. The content fits best under the category of M&A Activity (TAR) as it relates to merger proposals and takeover bids, specifically the sanctioning of a scheme of amalgamation by a regulatory tribunal.
2025-06-28 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter from Shilpa Medicare Limited addressed to stock exchanges, notifying the closure of the trading window for insiders ahead of the announcement of un-audited quarterly financial results for the quarter ended June 30, 2025. It does not contain any financial data or results itself, nor does it present or discuss the financial report. Instead, it is an announcement related to compliance with insider trading regulations and the timing of trading restrictions. The document length is short (1776 characters), and it serves as a regulatory notification rather than a report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2025-06-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the company's participation in an investor conference. It references Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, which governs disclosures about events such as investor meetings. The content is an intimation about a scheduled investor conference meeting, explicitly stating no unpublished price sensitive information will be discussed. The document is short (1836 characters) and serves as an announcement of an event rather than a detailed report or transcript. It does not contain financial data, earnings, management discussion, or any report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of a Q4 FY '25 earnings conference call for Shilpa Medicare Limited. It includes management commentary on quarterly and full-year financial performance, business updates across divisions, clinical study progress, regulatory approvals, and future outlook. The presence of a moderator, management speakers, and Q&A format typical of earnings calls is evident. The document is about 15,000 characters long, indicating it is a full transcript rather than a brief announcement or summary. The content focuses on quarterly financial results and operational updates, which aligns with the definition of a Call Transcript (CT).
2025-05-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.